
|Videos|September 13, 2022
Gregory Warren Discusses Measuring Value and Scaling Up Value-Based Contracting
Author(s)Laura Joszt, MA, Peter Wehrwein
Thus far, value-based contracts for prescription drugs has not been transformative because of the scalability challenge for payers, explained Gregory Warren, FSA, FCA, MAAA, partner and consulting actuary with Axene Health Partners.
Advertisement
Thus far, value-based contracts for prescription drugs has not been transformative because of the scalability challenge for payers, explained Gregory Warren, FSA, FCA, MAAA, partner and consulting actuary with Axene Health Partners.
Warren was the keynote speaker on day 2 of the 2022 PBMI Annual National Conference in Orlando, Florida.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
CVS Caremark to put Zepbound back on formulary and add Foundayo
2
Carveouts in healthcare safety net reform risk empowering middlemen
3
Eli Lilly acquires three vaccine companies for infectious disease portfolio
4
A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends
5




























